Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Egrifta
Tesamorelin is a synthetic growth hormone-releasing factor (GRF) analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. It works by mimicking the body's natural GRF, stimulating the pituitary gland to release growth hormone, which in turn helps to regulate metabolism and reduce visceral adipose tissue (VAT). Tesamorelin belongs to the class of growth hormone secretagogues.
Tesamorelin is used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy.
Outcome:
Additive effects on growth hormone levels
Mechanism:
Both substances stimulate growth hormone secretion.
Outcome:
May increase or decrease insulin requirements
Mechanism:
Tesamorelin can affect glucose metabolism.
Outcome:
May require adjustments in thyroid hormone dosage
Mechanism:
Tesamorelin can affect thyroid hormone metabolism.
Most likely new formulation: Sustained-release injectable formulation (2026, 70% confidence)
Based on current usage trends and ongoing research, there is a 20% likelihood of expanded indications for tesamorelin in the treatment of other metabolic disorders within the next 5 years.
Growth Hormone Secretagogue
Synthetic Growth Hormone-Releasing Factor Analog